* known diagnosis of previous pulmonary fibrosis or an interstitial lung disease. * clinical features or known diagnosis of malignancy or active non-covid-19 infection, including untreated latent tuberculosis. * history of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia. * known history of hypersensitivity to sirolimus. * history of unstable or deteriorating neurologic disease (including tias or stroke). * pregnant or lactating females. females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of birth control. * investigational therapy for any indication within 28 days prior to treatment. * current treatment with any drugs that are strong inhibitors of cyp3a4. * tofacitinib * clarithromycin * telithromycin * nefazodone * itraconazole * ketoconazole * atazanavir * darunavir * indinavir * lopinavir * nelfinavir * ritonavir * saquinavir * tipranavir. * inability or unwillingness to comply with the requirements for the trial.

* known diagnosis of previous pulmonary fibrosis or an interstitial lung disease. * clinical features or known diagnosis of malignancy or active non-covid-19 infection, including untreated latent tuberculosis. * history of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia. * known history of hypersensitivity to sirolimus. * history of unstable or deteriorating neurologic disease (including tias or stroke). * pregnant or lactating females. females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of birth control. * investigational therapy for any indication within 28 days prior to treatment. * current treatment with any drugs that are strong inhibitors of cyp3a4. * tofacitinib * clarithromycin * telithromycin * nefazodone * itraconazole * ketoconazole * atazanavir * darunavir * indinavir * lopinavir * nelfinavir * ritonavir * saquinavir * tipranavir. * inability or unwillingness to comply with the requirements for the trial.

- known diagnosis of previous pulmonary fibrosis or an interstitial lung disease. - clinical features or known diagnosis of malignancy or active non-covid-19 infection, including untreated latent tuberculosis. - history of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia. - known history of hypersensitivity to sirolimus. - history of unstable or deteriorating neurologic disease (including tias or stroke). - pregnant or lactating females. females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of birth control. - investigational therapy for any indication within 28 days prior to treatment. - current treatment with any drugs that are strong inhibitors of cyp3a4. - tofacitinib - clarithromycin - telithromycin - nefazodone - itraconazole - ketoconazole - atazanavir - darunavir - indinavir - lopinavir - nelfinavir - ritonavir - saquinavir - tipranavir. - inability or unwillingness to comply with the requirements for the trial.

- known diagnosis of previous pulmonary fibrosis or an interstitial lung disease. - clinical features or known diagnosis of malignancy or active non-covid-19 infection, including untreated latent tuberculosis. - history of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia. - known history of hypersensitivity to sirolimus. - history of unstable or deteriorating neurologic disease (including tias or stroke). - pregnant or lactating females. females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of birth control. - investigational therapy for any indication within 28 days prior to treatment. - current treatment with any drugs that are strong inhibitors of cyp3a4. - tofacitinib - clarithromycin - telithromycin - nefazodone - itraconazole - ketoconazole - atazanavir - darunavir - indinavir - lopinavir - nelfinavir - ritonavir - saquinavir - tipranavir. - inability or unwillingness to comply with the requirements for the trial.